secondary outcome measures

secondary outcome measures

The outcome measures in a clinical trial that provide information on therapeutic effects of secondary importance, side effects or tolerability. Data on secondary outcomes are used to evaluate additional effects of the intervention not included in the primary outcome measure.
References in periodicals archive ?
There were no differences between groups in a secondary outcome measures, including positive provocative stress testing and changes in UDI, PCI-I, Incontinence Severity Index, and quality-of-life measures.
Secondary outcome measures included changes in the Aberrant Behavior Checklist (ABC) and the Social Responsiveness Scale (SRS).
Secondary outcome measures include progression-free survival, overall survival, and exploratory predictors of outcome assessed by IL4R expression in archived tumor biopsies.
Dupilumab, a fully human monoclonal antibody that binds specifically to the shared alpha chain subunit of the interleukin-4 and -13 receptors, hit all of its primary and secondary outcome measures in the two trials, known as SOLO 1 and SOLO 2.
Secondary outcome measures included the percentage of subjects whose serum uric acid levels have decreased to < 6.
Of the secondary outcome measures, objective response was seen in two of three patients on cobimetinib, compared with fewer than half of the placebo arm patients (68% vs.
Secondary outcome measures were systolic BP (SBP) and diastolic BP (DBP) at the end of treatment.
Secondary outcome measures were analysed for all of the data from the multiple time points (for Pre/Post S1, S2, S3, S4, and S5) for the isometric maximum trunk flexion /extension and VAS.
Secondary outcome measures were stroke, stroke and ischaemic heart disease combined, and mortality.
There also were no differences between the groups in scores on secondary outcome measures, including the Brief Pain Inventory which measures pain-related interference with activities; the Swiss Spinal Stenosis Questionnaire (SSSQ), which measures pain, function, and satisfaction with treatment; the EQ-5D, which measures quality of life; or the Generalized Anxiety Disorder-7 scale.
ORLANDO -- Duloxetine for the treatment of late-life depression missed its primary end point in a recent large randomized trial, but it did result in consistently significant clinical improvement, compared with placebo across numerous secondary outcome measures.
Secondary outcome measures include response duration, safety and pharmacokinetics of MOR208.